Ceregene announced that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b trial to treat Parkinson’s disease. This multi-center, sham-surgery, double-blinded controlled trial will recruit approximately 52 patients at 11 sites in the U.S. It is designed to test whether CERE-120, when delivered to the degenerating neuronal cell bodies (in the substantia nigra) as well as the terminals of these neurons (in the putamen) can restore sufficient function to produce meaningful clinical benefit. Half of the study subjects will undergo brain surgery to receive CERE-120, while the other half will undergo a similar surgery without receiving any CERE-120 injections (“sham” or “mock” surgery).
CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin, a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and restoring normal function.
For more information call (858) 458-8800 or visit www.ceregene.com.